# 2022 International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST) > **NIH NIH R13** · DUKE UNIVERSITY · 2022 · $70,000 ## Abstract Abstract. The most recent UNAIDS estimates of the global burden of HIV are that 38 million people are living with HIV- 1 infection worldwide, with 68% of them residing in sub-Saharan Africa. A striking difference exists between the east/southern and the west/central regions of sub-Saharan Africa, with reductions in AIDS-related deaths since 2010 of 49% and 37%, respectively. Clearly, much work remains in terms of training local physicians and scientists in the diagnosis, treatment, and management of individuals with HIV-1 infection; conducting implementation science to determine the most cost-effective use of financial and human resources; and ensuring evidence-informed public health policy and programming to reduce disparities in the AIDS response across Africa's sub-regions. Despite treatment likely having contributed to slowing HIV transmission, HIV prevention remains critical to stem the tide of HIV. In fact, a second AIDS pandemic in the next 12 years is predicted due to 1) changing demographics in Africa with increasing numbers of youth, 2) increasing transmitted viral drug resistance, and 3) increased cost and limited availability of 2nd and 3rd line treatment regimens. Taken together, these factors suggest that the total number of people living with AIDS may increase by 2 million/year to reach a staggering 50 million worldwide by 2030. Since 2007, 14 successful annual INTEREST Conferences, known as the `African CROI', have brought together scientists involved in HIV diagnosis and treatment, pathogenesis, and prevention research in resource- limited settings in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents. Planning and organization of the 2022 INTEREST Conference will be overseen by the Amsterdam Institute of Global Health and Development. Dr. Kwasi Torpey (University of Ghana School of Public Health/Amsterdam Institute for Global Health and Development) chairs INTEREST's International Conference Committee (ICC) and is the new Scientific Chair of INTEREST. The organizers of the 2022 INTEREST Conference will pursue the following objectives: 1) To provide cutting-edge knowledge in the fields of diagnosis and treatment, pathogenesis and prevention of HIV-1 for adults, including the elderly, adolescents and children living with HIV in Africa, in order to contribute to achieving the 95-95-95 viral suppression goal and to preventing a second great HIV pandemic. 2) To foster new research interactions among leading investigators and those who represent the potential future scientific leadership for health care and research on the African continent. ## Key facts - **NIH application ID:** 10479531 - **Project number:** 1R13AI170098-01 - **Recipient organization:** DUKE UNIVERSITY - **Principal Investigator:** Guido Ferrari - **Activity code:** R13 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2022 - **Award amount:** $70,000 - **Award type:** 1 - **Project period:** 2022-04-21 → 2023-03-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10479531 ## Citation > US National Institutes of Health, RePORTER application 10479531, 2022 International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST) (1R13AI170098-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10479531. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*